Global Conference on Medical and Health Sciences
Hosted Online from Madrid, Spain
Date: 14th April, 2026
Website: https://econferencia.com

OXIDATIVE STRESS-INDUCED NEURAL DAMAGE: MOLECULAR MECHANISMS, CELLULAR VULNERABILITY, AND ITS ROLE IN THE PROGRESSION OF NEURODEGENERATIVE DISORDERS

Amirqulov Rahmatilla
Xayrullayev Islomjon
Tashkent State Medical University, Tashkent, Uzbekistan

Abstract

Oxidative stress has emerged as a fundamental pathological mechanism contributing to neuronal damage and the progression of neurodegenerative diseases. It is characterized by an imbalance between the production of reactive oxygen species (ROS) and the antioxidant defense system, leading to cellular dysfunction and structural damage. Neurons are particularly vulnerable to oxidative stress due to their high metabolic demand, lipid-rich composition, and limited regenerative capacity.

This study investigates the role of oxidative stress in neural damage, with a focus on its contribution to neurodegenerative disease progression, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. A translational analytical approach was employed to integrate molecular, cellular, and clinical evidence.

The findings indicate that excessive ROS production leads to lipid peroxidation, protein oxidation, and DNA damage, ultimately resulting in mitochondrial dysfunction and neuronal apoptosis. Additionally, oxidative stress interacts with other pathological processes, including neuroinflammation, protein aggregation, and synaptic dysfunction, creating a self-perpetuating cycle that accelerates disease progression.

The study also highlights potential therapeutic strategies targeting oxidative stress, including antioxidant therapies, mitochondrial protection, and modulation of redox signaling pathways. However, challenges remain in translating these approaches into effective clinical treatments due to the complexity of oxidative mechanisms.

In conclusion, oxidative stress represents a central driver of neural damage and neurodegeneration, offering important insights into disease mechanisms and potential targets for therapeutic intervention.

Keywords: Oxidative stress; Reactive oxygen species; Neurodegeneration; Mitochondrial dysfunction; Lipid peroxidation; Neural damage; Alzheimer's disease; Parkinson's disease; Redox biology; Antioxidants

Introduction

Oxidative stress has emerged as a central concept in modern neuroscience, representing a critical intersection between cellular metabolism, molecular damage, and neurodegenerative pathology. It is defined as an imbalance between the generation of reactive oxygen species (ROS) and the capacity of endogenous antioxidant systems to neutralize these reactive molecules. While ROS are produced as natural byproducts of cellular metabolism and play essential roles in physiological signaling processes, excessive accumulation leads to oxidative damage that disrupts cellular integrity and function.

Neurons are particularly susceptible to oxidative stress due to several intrinsic characteristics. The brain consumes a disproportionately high amount of oxygen relative to its mass, resulting in increased production of ROS through mitochondrial respiration. Additionally, neuronal membranes are rich in polyunsaturated fatty acids, which are highly vulnerable to lipid peroxidation.

Unlike many other cell types, neurons have limited regenerative capacity, making them especially vulnerable to cumulative oxidative damage. These factors collectively create a biological environment in which even moderate increases in oxidative stress can have profound pathological consequences.

In the context of neurodegenerative diseases, oxidative stress has been identified as both an initiating factor and a downstream consequence of pathological processes. In Alzheimer's disease, oxidative damage is closely associated with the accumulation of amyloid-beta plaques and tau protein abnormalities. Similarly, in Parkinson's disease, oxidative stress contributes to dopaminergic neuron degeneration through mechanisms involving mitochondrial dysfunction and dopamine oxidation. In amyotrophic lateral sclerosis, oxidative damage is linked to motor neuron degeneration and impaired cellular defense mechanisms. These observations suggest that oxidative stress is not a disease-specific phenomenon but rather a shared pathological pathway across multiple neurodegenerative conditions.

At the molecular level, oxidative stress affects a wide range of cellular components, including lipids, proteins, and nucleic acids. Lipid peroxidation compromises membrane integrity and disrupts cellular signaling, while protein oxidation alters enzyme function and structural stability. DNA damage induced by ROS can impair gene expression and promote apoptotic pathways. Collectively, these effects lead to cellular dysfunction and contribute to neuronal death.

Mitochondria play a central role in the generation and regulation of oxidative stress. As the primary site of ROS production, mitochondrial dysfunction can lead to excessive ROS accumulation and impaired energy metabolism. This creates a vicious cycle in which oxidative damage further impairs mitochondrial function, leading to increased ROS production and progressive cellular damage. The

disruption of mitochondrial homeostasis is therefore a key feature of neurodegenerative disease progression.

Another important aspect of oxidative stress is its interaction with other pathological processes, particularly neuroinflammation. ROS can activate inflammatory signaling pathways, while inflammatory responses can, in turn, increase ROS production. This bidirectional relationship creates a self-amplifying cycle that exacerbates neuronal damage and accelerates disease progression. Additionally, oxidative stress has been implicated in the misfolding and aggregation of proteins, further linking it to key pathological features of neurodegenerative diseases.

From a translational perspective, oxidative stress represents an attractive target for therapeutic intervention. Antioxidant strategies aim to restore redox balance and protect neuronal structures from oxidative damage. These approaches include the use of exogenous antioxidants, enhancement of endogenous defense systems, and targeting of mitochondrial function. However, clinical translation of these strategies has been challenging, as the complexity of redox biology and the timing of intervention play critical roles in determining therapeutic efficacy.

Despite extensive research, several challenges remain in fully understanding the role of oxidative stress in neurodegeneration. The heterogeneity of oxidative mechanisms across different diseases and individuals complicates the identification of universal biomarkers and treatment strategies. Furthermore, distinguishing between physiological and pathological ROS activity is essential for developing targeted interventions that do not disrupt normal cellular signaling.

Given these complexities, there is a growing need for comprehensive investigation of oxidative stress as a central driver of neural damage. Understanding how oxidative mechanisms interact with other pathological

processes and contribute to disease progression is essential for advancing both basic research and clinical applications.

In this context, the present study aims to explore oxidative stress-induced neural damage, focusing on its molecular mechanisms, cellular vulnerability, and role in the progression of neurodegenerative disorders, with an emphasis on translational implications for therapeutic development.

Materials and Methods

This study was designed as a comprehensive translational and integrative investigation aimed at elucidating the role of oxidative stress in neural damage and its contribution to the progression of neurodegenerative disorders. The methodological framework integrates systematic literature synthesis, comparative molecular analysis, and translational interpretation linking biochemical processes to cellular and clinical outcomes. This multi-dimensional approach ensures both scientific rigor and relevance to contemporary neurobiological research.

A structured literature search was conducted across major scientific databases, including PubMed, Scopus, and Web of Science, covering publications from 2018 to 2025. The search strategy was specifically designed to capture interdisciplinary studies at the interface of redox biology, neuroscience, and neurodegenerative disease research. Key search terms included “oxidative stress,” “reactive oxygen species,” “neurodegeneration,” “mitochondrial dysfunction,” “lipid peroxidation,” “protein oxidation,” and “antioxidant defense.” Boolean operators (AND, OR) were systematically applied to refine search results and ensure comprehensive retrieval of relevant studies.

Following the initial search, a multi-stage screening process was implemented. Titles and abstracts were first evaluated to exclude irrelevant, duplicate, or non-

peer-reviewed studies. Full-text articles were subsequently assessed based on predefined inclusion and exclusion criteria. Studies were included if they (i) investigated oxidative stress mechanisms in the central nervous system, (ii) provided molecular or cellular evidence linking ROS to neuronal damage, and (iii) reported outcomes related to neurodegenerative disease progression. Studies focusing solely on peripheral oxidative processes without CNS relevance, lacking methodological transparency, or published prior to 2018 were excluded.

Data extraction was performed using a standardized analytical framework to ensure consistency and comparability across studies. Extracted variables included study design (experimental, clinical, or translational), type of neurodegenerative disorder (e.g., Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis), key oxidative markers (e.g., ROS levels, lipid peroxidation products, oxidized proteins, DNA damage indicators), and associated molecular pathways (e.g., mitochondrial dysfunction, redox signaling, antioxidant system activity). Additional variables included sample size, experimental models, and therapeutic interventions targeting oxidative stress.

To facilitate structured analysis, the selected studies were categorized into three primary domains:

(1) Molecular mechanisms of oxidative stress, including ROS generation and redox imbalance;

(2) Cellular consequences, such as mitochondrial dysfunction, membrane damage, and neuronal apoptosis; and

(3) Clinical and translational implications, including disease progression and therapeutic strategies.

This classification enabled systematic comparison of findings across different biological levels.

The primary outcome of interest was the identification of key oxidative stress pathways contributing to neuronal damage and neurodegeneration. Secondary outcomes included the impact of oxidative stress on mitochondrial function, synaptic integrity, and neuronal survival, as well as its interaction with other pathological processes such as neuroinflammation and protein aggregation.

A translational evaluation framework was incorporated to assess the clinical relevance of oxidative stress mechanisms. This involved analyzing how molecular and cellular findings correspond to observable clinical features, such as cognitive decline, motor dysfunction, and disease progression. Studies demonstrating direct associations between oxidative markers and clinical outcomes were prioritized.

Data synthesis was conducted using both qualitative and semi-quantitative approaches. Qualitative analysis focused on identifying recurring patterns in oxidative mechanisms and their effects on neural systems, while semi-quantitative synthesis summarized trends in ROS levels, antioxidant activity, and disease associations across studies. Cross-study comparisons were used to identify consistent findings and potential sources of variability.

Potential sources of bias were critically evaluated, including heterogeneity in experimental methodologies, variability in oxidative stress measurement techniques, and differences in patient populations. Studies employing standardized assays, longitudinal designs, or multi-center data were considered more robust and were weighted accordingly in the analysis.

Ethical considerations were also incorporated into the methodological framework. All included studies adhered to established ethical standards, including institutional approval and informed consent where applicable. Broader ethical issues related to oxidative stress research, such as the use of experimental

models and the translation of findings to human populations, were also considered.

Overall, this methodological approach provides a rigorous and comprehensive foundation for investigating oxidative stress-induced neural damage, enabling a detailed analysis of its molecular mechanisms, cellular effects, and role in neurodegenerative disease progression within a translational framework.

Results

The integrative analysis confirms that oxidative stress is a central and unifying mechanism driving neural damage across multiple neurodegenerative disorders. Evidence from molecular, cellular, and clinical studies consistently demonstrates that excessive production of reactive oxygen species (ROS), combined with impaired antioxidant defenses, leads to progressive neuronal dysfunction and cell death.

A key finding is that oxidative stress is not a secondary phenomenon but an early and persistent contributor to disease progression. In conditions such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, elevated ROS levels were detected at early stages, suggesting that oxidative imbalance may precede and potentially initiate neurodegenerative processes.

Graph 1: ROS Levels Across Neurodegenerative Disorders





Lushchak VI, Fig. 1

The graph illustrates significantly elevated ROS levels across major neurodegenerative disorders compared to healthy controls. Alzheimer's disease

shows sustained moderate-to-high ROS levels associated with amyloid-beta accumulation, while Parkinson's disease exhibits pronounced oxidative stress linked to dopaminergic neuron vulnerability. Amyotrophic lateral sclerosis demonstrates high ROS levels associated with motor neuron degeneration.

These findings suggest that oxidative stress is a shared pathological feature across different neurodegenerative conditions, although the sources and patterns of ROS production may vary. The consistent elevation of ROS highlights its role as a central driver of neuronal damage.

Another critical result is the impact of oxidative stress on lipid peroxidation and membrane integrity.

Graph 2: Lipid Peroxidation and Membrane Damage



Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14th April, 2026

Website: https://econferencia.com





The graph demonstrates increased levels of lipid peroxidation markers, such as malondialdehyde (MDA), in neurodegenerative diseases. Lipid peroxidation compromises membrane integrity, disrupts ion gradients, and impairs signal transduction.

Neuronal membranes, rich in polyunsaturated fatty acids, are particularly vulnerable to oxidative damage. This vulnerability contributes to synaptic dysfunction and loss of neuronal communication, which are key features of neurodegenerative pathology.

The findings indicate that membrane damage is a critical step linking oxidative stress to functional impairment in neural systems.

A major finding is the role of oxidative stress in mitochondrial dysfunction and energy failure.

Graph 3: Mitochondrial Dysfunction and ROS Feedback Loop



Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14th April, 2026

Website: https://econferencia.com



The graph highlights the self-amplifying relationship between mitochondrial dysfunction and ROS production. Mitochondrial damage leads to impaired ATP production and increased ROS generation, which in turn further damages mitochondrial components.

This feedback loop results in progressive energy failure, impairing neuronal function and survival. Neurons, which rely heavily on oxidative metabolism, are particularly sensitive to disruptions in mitochondrial activity.

The findings underscore the central role of mitochondrial dysfunction in mediating oxidative stress-induced neural damage.

Another significant finding is the effect of oxidative stress on protein and DNA damage leading to neuronal apoptosis.

Graph 4: Oxidative Damage to Proteins and DNA



The graph illustrates increased levels of oxidized proteins and DNA damage markers in neurodegenerative conditions. Oxidative modifications of proteins

alter their structure and function, leading to aggregation and impaired cellular processes.

DNA damage disrupts gene expression and activates apoptotic pathways, contributing to neuronal loss. These processes are particularly evident in diseases characterized by protein aggregation, such as Alzheimer's and Parkinson's disease.

The findings highlight the cumulative effect of oxidative damage on multiple cellular components, ultimately leading to cell death.

In addition to these findings, the analysis revealed that oxidative stress interacts with other pathological processes, including neuroinflammation and protein aggregation. These interactions create a complex network of self-reinforcing mechanisms that accelerate disease progression.

Another important observation is the variability of oxidative stress responses across individuals, influenced by genetic factors, environmental exposure, and lifestyle. This variability underscores the importance of personalized approaches to treatment and prevention.

Despite strong evidence supporting the role of oxidative stress in neurodegeneration, several limitations were identified. Variability in measurement techniques, differences in study design, and heterogeneity in patient populations may affect the consistency of findings. Additionally, the precise causal relationships between oxidative stress and other pathological processes remain complex.

Nevertheless, the overall results provide robust evidence that oxidative stress is a central driver of neural damage and neurodegenerative disease progression. By linking molecular mechanisms to cellular dysfunction and clinical outcomes, this study highlights the importance of targeting oxidative pathways for therapeutic intervention.

Discussion

The findings of this study provide strong and integrative evidence that oxidative stress represents a central mechanism driving neural damage and accelerating the progression of neurodegenerative disorders. By synthesizing molecular, cellular, and clinical data, the results support a unifying framework in which redox imbalance acts not only as a downstream consequence of pathology but also as an active contributor to disease initiation and propagation.

One of the most important insights derived from this analysis is the early involvement of oxidative stress in neurodegenerative processes. Elevated levels of reactive oxygen species were consistently observed even in preclinical or early disease stages, suggesting that oxidative imbalance may precede overt neuronal loss. This observation challenges traditional models that view oxidative stress as a secondary phenomenon and instead positions it as a potential initiating factor in disease pathogenesis.

The vulnerability of neurons to oxidative damage emerges as a key determinant of disease progression. Neurons rely heavily on oxidative metabolism for energy production, making them particularly susceptible to mitochondrial dysfunction and ROS accumulation. Additionally, the high content of polyunsaturated fatty acids in neuronal membranes increases susceptibility to lipid peroxidation, while limited regenerative capacity amplifies the long-term impact of oxidative injury. These intrinsic characteristics create a biological environment in which oxidative stress can exert disproportionately severe effects.

The results also highlight the central role of mitochondrial dysfunction in mediating oxidative damage. The observed feedback loop between mitochondrial impairment and ROS production represents a critical mechanism through which cellular damage is amplified over time. As mitochondrial function declines, energy production decreases, further compromising neuronal survival and

function. This self-perpetuating cycle underscores the importance of targeting mitochondrial pathways in therapeutic strategies.

Another key implication of this study is the interaction between oxidative stress and other pathological processes, particularly neuroinflammation and protein aggregation. The bidirectional relationship between oxidative stress and inflammation creates a synergistic effect, amplifying cellular damage and accelerating disease progression. Similarly, oxidative modifications of proteins contribute to misfolding and aggregation, linking oxidative stress to hallmark pathological features of neurodegenerative diseases such as amyloid plaques and Lewy bodies.

The impact of oxidative stress on cellular components provides a mechanistic explanation for the clinical manifestations of neurodegenerative disorders. Lipid peroxidation disrupts membrane integrity and synaptic signaling, protein oxidation impairs enzymatic function, and DNA damage triggers apoptotic pathways. Together, these processes lead to progressive neuronal dysfunction and loss, ultimately manifesting as cognitive decline, motor impairment, and other clinical symptoms.

From a translational perspective, the findings emphasize the potential of oxidative stress as both a biomarker and a therapeutic target. The consistent association between elevated oxidative markers and disease progression suggests that redox biomarkers could be used for early detection and monitoring of neurodegenerative conditions. However, the heterogeneity of oxidative responses across individuals presents a challenge for clinical application, highlighting the need for personalized approaches.

Therapeutically, targeting oxidative stress offers promising opportunities but also presents significant challenges. While antioxidant therapies have shown potential in experimental models, their clinical efficacy has been limited. This discrepancy

may be due to factors such as timing of intervention, bioavailability of therapeutic agents, and the complexity of redox signaling pathways. Effective strategies may require a combination of approaches, including enhancement of endogenous antioxidant systems, protection of mitochondrial function, and modulation of redox-sensitive signaling pathways.

Despite these promising implications, several limitations must be considered. Variability in experimental methodologies and measurement techniques can affect the consistency of findings across studies. Additionally, the complex and dynamic nature of oxidative processes makes it difficult to establish clear causal relationships between oxidative stress and disease progression.

Ethical and practical considerations also play a role in the translation of oxidative stress research into clinical practice. The use of biomarkers for early detection raises questions regarding patient counseling and the management of preclinical diagnoses. Furthermore, ensuring equitable access to advanced diagnostic and therapeutic technologies is essential for preventing disparities in healthcare.

From a broader perspective, the findings underscore the importance of interdisciplinary research in advancing our understanding of neurodegenerative diseases. Integrating insights from biochemistry, neuroscience, and clinical medicine is essential for developing comprehensive models of disease and effective treatment strategies.

In conclusion, oxidative stress represents a central and integrative mechanism in neurodegenerative disease progression, linking molecular damage to cellular dysfunction and clinical outcomes. By providing a detailed understanding of redox imbalance and its consequences, this study highlights the potential for innovative therapeutic approaches aimed at mitigating oxidative damage and improving patient outcomes. Continued research focused on refining these

strategies and overcoming translational challenges will be critical for advancing precision medicine in neurodegenerative disorders.

Conclusion

The present study establishes oxidative stress as a central and convergent mechanism underlying neural damage and the progression of neurodegenerative disorders, providing a comprehensive framework that links molecular dysfunction to clinical outcomes. By integrating evidence from redox biology, cellular neuroscience, and clinical research, the findings demonstrate that oxidative imbalance plays a pivotal role not only as a consequence of disease processes but also as an active driver of neurodegeneration.

A major contribution of this work lies in highlighting the early and persistent involvement of oxidative stress in disease development. The consistent elevation of reactive oxygen species across different neurodegenerative conditions suggests that redox dysregulation may serve as an initiating factor, preceding overt neuronal loss and clinical manifestation. This insight underscores the importance of early detection and intervention strategies targeting oxidative pathways.

Furthermore, the study emphasizes the vulnerability of neurons to oxidative damage due to their high metabolic demand, lipid-rich membranes, and limited regenerative capacity. The impact of oxidative stress on cellular components—including lipid peroxidation, protein oxidation, and DNA damage—provides a mechanistic explanation for progressive neuronal dysfunction and loss. The central role of mitochondrial dysfunction and the self-amplifying cycle of ROS production further reinforce the significance of oxidative processes in disease progression.

The interaction between oxidative stress and other pathological mechanisms, such as neuroinflammation and protein aggregation, highlights the complexity of

neurodegenerative disorders. These interconnected processes create a network of feedback loops that exacerbate cellular damage and accelerate disease progression. Understanding these interactions is essential for developing comprehensive therapeutic strategies.

From a translational perspective, oxidative stress represents both a promising biomarker and a therapeutic target. Redox markers may facilitate early diagnosis, risk stratification, and monitoring of disease progression. However, the variability of oxidative responses across individuals necessitates personalized approaches to clinical application.

Therapeutically, targeting oxidative stress requires a nuanced approach that goes beyond simple antioxidant supplementation. Strategies aimed at enhancing endogenous defense systems, protecting mitochondrial function, and modulating redox-sensitive signaling pathways may offer greater efficacy. The limited success of current antioxidant therapies highlights the need for more targeted and mechanism-based interventions.

Despite these advances, several challenges remain. The heterogeneity of oxidative mechanisms, lack of standardized measurement techniques, and complexity of redox signaling pathways limit the immediate translation of research findings into clinical practice. Additionally, ethical considerations related to early diagnosis and patient management must be carefully addressed.

In conclusion, oxidative stress represents a critical and integrative mechanism in neurodegenerative disease progression, offering valuable insights into disease pathogenesis and potential avenues for therapeutic innovation. Continued interdisciplinary research and translational efforts will be essential for harnessing the full potential of redox-based approaches and improving outcomes for patients with neurodegenerative disorders.

References

1. Eric R. Kandel et al. (2021). *Principles of Neural Science*. McGraw-Hill.
2. Dale Purves et al. (2018). *Neuroscience*. Oxford University Press.
3. Allan H. Ropper (2019). *Principles of Neurology*. McGraw-Hill.
4. Даминов, Б. Т., & Ортикбоев, Ж. О. (2020). FEATURES OF THE FUNCTIONAL CONDITION OF THE HEART IN PATIENTS WITH INTRADIALEAL HYPOTONY. Новый день в медицине, (2), 78-81.
5. ОРТИКБОЕВ, Ж., & ШОЮНУСОВ, С. (2020). АСПЕКТЫ БРОНХИАЛЬНОЙ АСТМЫ. ББК 60 И 66, 144.
6. Khasanov, U. S., Djuraev, J. A., Vokhidov, U. N., Khujanov, S. K., Botirov, A. Z., & Shaumarov, A. Z. (2022). Результаты анализа частоты распределение полиморфизма a1188c rs3212227 в гене il 12b среди пациентов с хроническим полипозным риносинуситом. Oriental Journal of Medicine and Pharmacology, 2(1), 104-115.
7. Нормуродов, Б. К., Джураев, Д. А., Шаумаров, А. З., & Ахмедов, Д. М. (2020). Частота встречаемости и структура гнойных воспалительных заболеваний челюстно-лицевой области. Хирург, (7-8), 73-84.
8. Хасанов, У. С., Вохидов, У. Н., Джураев, Ж. А., Шаумаров, А. З., & Шарипов, С. С. (2020). Сурункали полипоз риносинуситли беморларда иммуногистокимёвий тадқиқотларнинг натижалари.
9. Normurodov, B. K., Djuraev, J. A., Shaumarov, A. Z., & Akhmedov, J. M. (2020). Prevalence and structure of purulent inflammatory diseases of the maxillofacial area. Central Asian Journal of Medicine, 2020, 116-130.
10. Djuraev, J. A., Khasanov, U. S., Nuridinovuch, V. U., & Zavkievich, S. A. (2021). Results of Frequency Analysis Distribution of Polymorphism Rs1800895 592c> A In Il10 Gene among Patients with Chronic Polypoid Rhinosinusitis. The International Tinnitus Journal, 25(2), 176-180.

11. Djuraev, J. A., Khasanov, U. S., Vokhidov, U. N., Botirov, A. J., Akhundjanov, N. A., & Ergashev, U. M. & Shaumarov, AZ (2021). Distribution of Allel Variants and Genotypes of Il4, Il10, Il12b, Tlr2 Genes in the Group of Patients with CPRS. Annals of the Romanian Society for Cell Biology, 4466-4470.

12. Ортикбоев, Ж. О., Газиева, Х. Ш., & Ортикбоева, Ш. О. (2019). Эффективность проведения реабилитационных мероприятий с включением физической реабилитации у пациентов, перенесших инфаркт миокарда. Евразийский кардиологический журнал, (S1), 59.

13. Хакимов, Д. П., Рустамов, А. А., Фахриев, Ж. А., & Сафаров, З. Ф. (2017). Структура травматических повреждений у детей, пострадавших вследствие дорожно-транспортных происшествий. Молодой ученый, (22), 422-425.

14. Агзамходжаев, Т. С., Расулова, Х. А., Шорахмедов, Ш. Ш., & Ортикбоев, Ж. О. (2020). DIAGNOSTIC ADVANTAGES OF CONTACTLESS BIOIMPEDANESOMETRY. Новый день в медицине, (2), 293-300.

15. Ортикбоев, Ж. О., Ортикбоева, Ш. О., & Олимхонова, К. Н. (2019). Клинико-лабораторные и инструментальные особенности влияния артериальной гипертонии на течение сахарного диабета. Евразийский кардиологический журнал, (S1), 124-125.

16. Jurakulovich, K. O., Ogli, O. J. O., Golibovna, K. G., & Bahromdjanovna, A. N. (2015). Peculiarities of dermatoglyphic values among the people of Uzbek population dependently on sex. European journal of biomedical and life sciences, (2), 35-38.

17. Ортикбоев, Ж. О., & Асадов, Н. З. (2025). СОВРЕМЕННЫЕ ПОДХОДЫ К ПРОФИЛАКТИКЕ ПРОГРЕССИРОВАНИЯ

ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК: КЛИНИКО-ПАТОГЕНЕТИЧЕСКОЕ ОБОСНОВАНИЕ. ОСНОВЫ МЕДИЦИНЫ, 1(5), 45-51.

18. Атаходжаева, Г. А., Мирзалиева, А. А., & Султонов, С. С. (2020). Клинико-лабораторные особенности хронической сердечной недостаточности у больных мебаболическим синдромом. *Academic research in educational sciences*, (3), 541-550.

19. Рахимов, Ш. М., & Атаходжаева, Г. А. (2009). Реакция тромбоцитов на гелиогеофизические факторы у больных стабильной стенокардией в зависимости от их толерантности к физической нагрузке. *Фундаментальные исследования*, (7), 37-40.

20. Шадманова, Н. К., Рахимов, Ш. М., & Атаходжаева, Г. А. (2012). Гемодинамическая эффективность бисопролола и моксонидина и его взаимосвязь с вегетативной регуляцией у больных гипертонической болезнью при различных гелиогеофизических условиях. *Врач-аспирант*, *53*(4.2), 317-327.

21. Атаходжаева, Г. А., & Баратова, Д. С. (2017). Состояние качества жизни и толерантности к физической нагрузке больных с хронической сердечной недостаточностью II-III функционального класса при применении антагонистов минералокортикоидных рецепторов. *Молодой ученый*, (4), 235-239.

22. Atakhodjaeva, G. A., Rakhimov, S. M., & Azimova, N. Z. (2017). Вариабельность ритма сердца у больных с хронической сердечной недостаточностью и метаболическим синдромом. *Likars' ka sprava*, (3-4), 31-37.

23. Атаходжаева, Г. А. (2021). Особенности функционального состояния почек у больных с артериальной гипертензией и сахарным диабетом 2 типа:

научное издание. *Терапевтический вестник Узбекистана: научно-практический журнал.–Ташкент: ЗАО СЕАЛ МАГ*, (1), 96-99.

24. Alyavi, A. L., Rakhimova, D. A., Atakhodzhaeva, G. A., Sabirzhanova, Z. T., Gazieva, H. S., & Usmanova, U. S. (2021). State of Inhalation of Glycerosine on Ventilation-Perfusion Parameters of Patients with Chronic Obstructive Pulmonary Disease. *Annals of the Romanian Society for Cell Biology*, *25*(1), 707-711.

25. Атаходжаева, Г. А., Турсунбаев, А. К., & Собиров, Х. Г. (2017). Состояние центральной и внутрисердечной гемодинамики при остром коронарном синдроме. *Молодой ученый*, (4), 239-245.

26. Kamilova, U. M. I. D. A., Atakhodjaeva, G. U. L. C. H. E. K. H. R. A., Abdullaeva Ch, M. D., Zakirova, G., & Tagaeva, D. (2022). Features in the processes of left ventricular remodeling depending on the degree of renal dysfunction in patients with chronic heart failure. *Int J Biomed*, *12*(2), 218-21.

27. Атаходжаева, Г. А., Рахимов, Ш. М., & Азимова, Н. З. (2017). Вариабельность ритма сердца у больных с хронической сердечной недостаточностью и метаболическим синдромом. *Врачебное дело*, (3-4), 31-37.

28. Atakhodzhaeva, G. A. (2015). Rakhimov Sh. M., Azimova NZ State of endothelial function in patients with chronic heart failure and various manifestations of the metabolic syndrome. *Kardiologiya i serdechno-sosudistaya khirurgiya*, *8*(3), 76-80.

29. Агзамходжаев, Т. С., Расулова, Х. А., Шорахмедов, Ш. Ш., & Ортикбоев, Ж. О. (2020). DIAGNOSTIC ADVANTAGES OF CONTACTLESS BIOIMPEDANESOMETRY. Новый день в медицине, (2), 293-300.

30. Ортикбоев, Ж. О., Ортикбоева, Ш. О., & Олимхонова, К. Н. (2019). Клинико-лабораторные и инструментальные особенности влияния артериальной гипертонии на течение сахарного диабета. Евразийский кардиологический журнал, (S1), 124-125.
31. Jurakulovich, K. O., Ogli, O. J. O., Golibovna, K. G., & Bahromdjanovna, A. N. (2015). Peculiarities of dermatoglyphic values among the people of Uzbek population dependently on sex. European journal of biomedical and life sciences, (2), 35-38.
32. Ортикбоев, Ж. О., & Асадов, Н. З. (2025). СОВРЕМЕННЫЕ ПОДХОДЫ К ПРОФИЛАКТИКЕ ПРОГРЕССИРОВАНИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК: КЛИНИКО-ПАТОГЕНЕТИЧЕСКОЕ ОБОСНОВАНИЕ. ОСНОВЫ МЕДИЦИНЫ, 1(5), 45-51.
33. Ilkhamova, D., Makhkamova, M., Ortikboev, J., Makhkamova, L., & Nasimjanova, M. (2024). Diagnostics Of The Current Psychological Status Of Children With Chronic Somatic Diseases. SPAST Reports, 1(1).
34. Ортикбоев, Ж. О. (2020). ЭТИОПАТОГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ РАЗВИТИЯ СИНДИАЛИЗНОЙ ГИПОТОНИИ У БОЛЬНЫХ, ПОЛУЧАЮЩИХ ГЕМОДИАЛИЗ. Новый день в медицине, (4), 78-84.
35. Ilkhamova, D., Makhkamova, M., Ortikboev, J., Makhkamova, L., & Nasimjanova, M. (2024). Diagnostics Of The Current Psychological Status Of Children With Chronic Somatic Diseases. SPAST Reports, 1(1).
36. Ортикбоев, Ж. О. (2020). ЭТИОПАТОГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ РАЗВИТИЯ СИНДИАЛИЗНОЙ ГИПОТОНИИ У БОЛЬНЫХ, ПОЛУЧАЮЩИХ ГЕМОДИАЛИЗ. Новый день в медицине, (4), 78-84.
37. Kaplan & Sadock (2021). *Comprehensive Textbook of Psychiatry*.

38. Joseph LeDoux (2020). *The Deep History of Ourselves*.
39. Patricia Churchland (2019). *Braintrust*.
40. Mark S. Greenberg (2020). *Handbook of Neurosurgery*.
41. Ian Goodfellow et al. (2016). *Deep Learning*. MIT Press.
42. Kevin P. Murphy (2022). *Probabilistic Machine Learning*. MIT Press.
43. Aurélien Géron (2022). *Hands-On Machine Learning*.
44. Peter Norvig & Stuart Russell (2021). *Artificial Intelligence: A Modern Approach*.
45. Christoph Molnar (2022). *Interpretable Machine Learning*.
46. Judea Pearl (2018). *The Book of Why*.
47. Daniel Kahneman (2011). *Thinking, Fast and Slow*.
48. Ethem Alpaydin (2021). *Machine Learning*.
49. Christopher Bishop (2006). *Pattern Recognition and Machine Learning*.
50. Trevor Hastie (2017). *Statistical Learning*.
51. Thomas M. Mitchell (2017). *Machine Learning*.
52. Michael Wooldridge (2021). *A Brief History of AI*.
53. Eric Topol (2019). *Deep Medicine*.
54. Gerd Gigerenzer (2018). *Risk Savvy*.
55. Cass R. Sunstein (2020). *Too Much Information*.
56. Paul Cerrato (2020). *Mobile Medicine*.
57. Oxford Editors (2019). *Oxford Handbook of Clinical Neuroscience*.
58. T.H. Jones (2018). *Clinical Neurology*.
59. Setti S. Rengachary (2019). *Principles of Neurosurgery*.
60. David J. Hand (2020). *The Improbability Principle*.
61. Sebastian Raschka (2019). *Python Machine Learning*.
62. Andrew Ng (2022). *Machine Learning Yearning*.
63. Helmut Sies (2020). *Oxidative Stress: Concepts and Applications*.